Preview Part 1
Preview Part 2
Array Biopharma ARRY presentations at AACR 2013:
The design and early development of the p38/Tie-2 inhibitor: Array-614 in hematologic cancers - Kevin Koch (link)
Part of an educational session so likely more of a review vs. new data.
MEK162, an allosteric MEK inhibitor promotes apoptosis and in vivo antitumor activity against human biliary cancer cell lines - J. Yang et al (Abstract 934)
A B-RAF-MEK complex reveals a kinase-independent role for BRAF in MAPK pathway suppression - M. Shiva et al (Abstract 2346)
Next-generation hypomethylator SGI-110 (click for intro)
Evaluation of oral bioavailability and intermittent dosing schedules for pharmacodynamic effects by SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA), in male cynomolgus monkeys - Oganesian et al (Abstract 678) Sunday 4/7
Non-human primate studies directly related to the ongoing phase 1/2 trial of SGI-110 in MDS/AML patients which was evaluating different dosing schedules for the next-generation DACOGEN (decitabine) drug.
The novel, small molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer - Tang et al (Abstract 4623)
Ovarian cancer is the solid tumor indication that ASTX has indicated that they will start a trial in in 2013. The two abstracts below may offer hints at other tumor possibilities, but the company has not specified.
SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome - Tellex et al (Abstract 679)
In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent, in hematologic malignancies - Covre et al (Abstract 680)
Other pipeline programs:
Novel aurora plus Bruton's tyrosine kinase-targeted therapies for aggressive B-cell non-Hodgkin's lymphoma - Mahadevan et al (Abstract 3388)
AT-IAP, a dual cIAP1 and XIAP antagonist with oral antitumor activity in melanoma models - Chessari et al (Abstract 2944)
A phase 2 study of Amuvatinib (MP-470), the first RAD51 inhibitor in combination with platinum-etoposide (PE) in refractory or relapsed small cell lung cancer (ESCAPE) - Byers et al (Abstract 2095)
The full data presentation for this SCLC trial - BDD readers were well ahead of the curve in expecting the abandonment of this drug candidate.
Presentations related Astex's HSP90 inhibitor AT13387 were covered in an earlier post.